Effects of clozapine and its metabolites on the 5-HT2 receptor system in cortical and hippocampal cells in vitro

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 28, Issue 2, 2004, Pages 297-302

  Heiser, Philip ^a   Schulte, Eva ^a   Hausmann, Christiane ^a   Becker, Ralf ^a   Remschmidt, Helmut ^a   Krieg, Jürgen Christian ^a   Vedder, Helmut ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Clozapine; Clozapine metabolites; Cortical cells; GAPDH; Serotonin receptor; SHS5Y5 cells

Indexed keywords

CLOZAPINE; CLOZAPINE N OXIDE; DRUG METABOLITE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MESSENGER RNA; NORCLOZAPINE; SEROTONIN RECEPTOR;

ANIMAL CELL; ARTICLE; BRAIN CELL; CELL DENSITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG RECEPTOR BINDING; ENZYME ACTIVITY; GENE EXPRESSION; HIPPOCAMPUS; HUMAN; HUMAN CELL; HUMAN VERSUS ANIMAL COMPARISON; NEUROBLASTOMA CELL; NONHUMAN; PROTEIN EXPRESSION; RAT; RECEPTOR AFFINITY; RECEPTOR DENSITY; SEROTONINERGIC SYSTEM;

EID: 1642482337     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2003.10.008     Document Type: Article

References (36)

1. Abi-Dargham A., Laruelle M., Aghajanian G.K., Charney D., Krystal J. The role of serotonin in the pathophysiology and treatment of schizophrenia. J. Neuropsychiatry Clin. Neurosci. 9:1997;1-17.
2. Ase A.R., Amdiss F., Hebert C., Huang N., van Gelder N.M., Reader T.A. Effects of antipsychotic drugs on dopamine and serotonin contents and metabolites, dopamine and serotonin transporters, and serotonin1A receptors. J. Neural Transm. 106:1999;75-105.
3. Baldessarini R.J., Centorrino F., Flood J.G., Volpicelli S.A., Huston-Lyons D., Cohen B.M. Tissue concentrations of clozapine and its metabolites in the rat. Neuropsychopharmacology. 9:1993;117-124.
4. Bollag D.M., Rozycki D.M., Edelstein S.J. Protein Methods. 2nd ed. 1996;Wiley-Liss, New York.
5. 2C receptors. Brain Res. Mol. Brain Res. 48:1997;45-52.
6. Burnet P.W., Chen C.P., McGowan S., Franklin M., Harrison P.J. The effects of clozapine and haloperidol on serotonin-1A, -2A and -2C receptor gene expression and serotonin metabolism in the rat forebrain. Neuroscience. 73:1996;531-540.
7. 2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology. 15:1996;442-455.
8. Dean B., Hayes W., Opeskin K., Naylor L., Pavey G., Hill C., Keks N., Copolov D.L. Serotonin2 receptors and the serotonin transporter in the schizophrenic brain. Behav. Brain Res. 73:1996;169-175.
9. 2-receptor occupancy in clozapine-treated patients. J. Clin. Psychiatry. 55(Suppl. B):1994;67-69.
10. Gaintner J.R., Jackson D.P., Maynert E.W. The action of thrombin on platelet 5-hydroxytryptamine. Bull. Johns Hopkins Hosp. 111:1962;185-197.
11. Grace A.A. Gating of information flow within the limbic system and the pathophysiology of schizophrenia. Brain Res. Brain Res. Rev. 2:2000;330-341.
12. Guitton C., Abbar M., Kinowski J.M., Chabrand P., Bressolle F. Multiple-dose pharmacokinetics of clozapine in patients with chronic schizophrenia. J. Clin. Psychopharmacol. 18:1998;470-476.
13. 2-dopamine receptor binding in the post-mortem human brain. An autoradiographic study. Eur. Neuropsychopharmacol. 5:1995;19-25.
14. Henning U., Loffler S., Krieger K., Klimke A. Uptake of clozapine into HL-60 promyelocytic leukaemia cells. Pharmacopsychiatry. 35:2002;90-95.
15. Henning U., Krieger K., Loffler S., Klimke A. Transport of clozapine and its major metabolites into human cells of glial and neuronal origin. Eur. Arch. Psychiatry Clin. Neurosci. 252(Suppl. 1):2002;210.
16. Heiser P., Schuler-Springorum M., Schulte E., Hausmann C., Remschmidt H., Krieg J.C., Vedder H. Pharmacokinetics of clozapine and its metabolites in hippocampal HT22 cells. Eur. J. Pharmacol. 476:2003;167-172.
17. Ichikawa J., Kuroki T., Dai J., Meltzer H.Y. Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens. Eur. J. Pharmacol. 19:1998;163-171.
18. Joseph M.H., Baker H.F., Crow A.J., Riley G.J., Risby D. Brain tryptophan metabolism in schizophrenia: a post-mortem study of metabolites on the serotonin and kynurenine pathways in schizophrenia and control subjects. Psychopharmacology. 62:1979;279-285.
19. Joyce J.N., Shane A., Lexow N., Winokur A., Casanova M.F., Kleinman J.E. Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology. 8:1993;315-336.
20. Lundberg T., Lindstrom L., Hartvig P., Reibring L., Agren H., Lundqvist H., Fasth K.J., Antoni G., Langstrom B. Serotonin-2 and dopamine-1 binding components of clozapine in frontal cortex and striatum in the human brain visualized by positron emission tomography. Psychiatry Res. 67:1996;1-10.
21. 2 receptor density in rat cerebral cortex. Life Sci. 45:1989;1397-1406.
22. Odou P., Frimat B., Fontaine B., Luyckx M., Brunet C., Robert H., Dine T., Gressier B., Cazin M., Cazin J.C. Determination of clozapine in serum by radioreceptor assay versus high-performance liquid chromatography: possible detection of hydroxy-metabolites. J. Clin. Pharm. Ther. 21:1996;337-342.
23. Ohuoha D.C., Hyde T.M., Kleinmann J.E. The role of serotonin in schizophrenia: an overview of the nomenclature, distribution and alterations of serotonin receptors in the central nervous system. Psychopharmacology (Berl.). 112:1993;5-15.
24. Peroutka S.J. Serotonin receptor variants in disease: new therapeutic opportunities? Ann. N. Y. Acad. Sci. 861:1998;16-25.
25. Remschmidt H., Schulz E., Martin M. An open trial of clozapine in thirty-six adolescents with schizophrenia. J. Child Adolesc. Psychopharmacol. 4:1994;31-41.
26. Sanders-Bush E. The serotonin receptors. 1998;3-4 Humana, Totowa.
27. Schreiber W., Opper C., Dickhaus B., Heiser P., Wesemann W., Krieg J.C. Alterations of blood platelet MAO-B activity and LSD-binding in humans after sleep deprivation and recovery sleep. J. Psychiatry Res. 31:1997;323-331.
28. Schulz E., Fleischhaker C., Clement H.W., Remschmidt H. Blood biogenic amines during clozapine treatment of early-onset schizophrenia. J. Neural Transm. 104:1997;1077-1089.
29. Seeman P. Receptor tables, vol. 2: drug dissociation constants for neuroreceptors and transporters. 1993;SZ Research, Toronto.
30. Seeman P. Atypical antipsychotics: mechanism of action. Can. J. Psychiatry. 47:2002;27-38.
31. Thomas D.R., Nelson D.R., Johnson A.M. Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology (Berl.). 93:1987;193-200.
32. 2A ligand 123I-5-I-R-91150. Br. J. Psychiatry. 173:1998;236-241.
33. Vedder H., Weiß I., Holsboer F., Reul J.M.H.M. Glucocorticoid and mineralcorticoid receptors in rat neocortical and hippocampal brain cells in culture: characterization and regulatory studies. Brain Res. 605:1993;18-24.
34. Vedder H., Bening-Abu-Shach U., Lanquillon S., Krieg J.C. Regulation of glucocorticoid receptor-mRNA in human blood cells by amitriptyline and dexamethasone. J. Psychiatry Res. 33:1999;303-308.
35. 2A receptors are expressed on pyramidal cells and interneurons in the rat cortex. Synapse. 27:1997;79-82.
36. Willins D.L., Berry S.A., Alsayegh L., Backstrom J.R., Sanders-Bush E., Freidman L., Roth B.L. Clozapine and other 5-hydroxytryptamine-2A receptor antagonists alter the subcellular distribution of 5-hydroxytryptamine-2A receptors in vitro and in vivo. Neuroscience. 91:1999;599-606.